Nitric oxide synthase inhibitors have antidepressant-like properties in mice 2. Chronic treatment results in downregulation of cortical beta-adrenoceptors

Citation
B. Karolewicz et al., Nitric oxide synthase inhibitors have antidepressant-like properties in mice 2. Chronic treatment results in downregulation of cortical beta-adrenoceptors, EUR J PHARM, 372(3), 1999, pp. 215-220
Citations number
60
Categorie Soggetti
Pharmacology & Toxicology
Journal title
EUROPEAN JOURNAL OF PHARMACOLOGY
ISSN journal
00142999 → ACNP
Volume
372
Issue
3
Year of publication
1999
Pages
215 - 220
Database
ISI
SICI code
0014-2999(19990521)372:3<215:NOSIHA>2.0.ZU;2-5
Abstract
Down-regulation of cortical beta-adrenoceptors is observed in rodents follo wing chronic treatment with many clinically effective antidepressant therap ies. [H-3]dihydroalprenolol binding to cortical beta-adrenoceptors was exam ined in mice treated with the nitric oxide (NO) synthase antagonist N-G-nit ro-L-arginine (L-NNA). Administration of L-NNA (0.1, 0.3 mg/kg) for 21 days produced a significant reduction (28%, 31%, respectively, P < 0.05) in [H- 3]dihydroalprenolol binding to cortical membranes without affecting K-d. Do se 1 mg/kg of L-NNA given chronically also produced a 20% decrease in beta- adrenoceptor density, but this effect was not statistically significant. Wh ile chronic treatment with imipramine (15 and 30 mg/kg) produced respective ly a 30% and 25% (P < 0.05) reduction in the density of [H-3]dihydroalpenol ol, single injection of either imipramine (15 and 30 mg/kg) or L-NNA (0.1, 0.3, and 1 mg/kg) had no effect on [H-3]dihydroalprenolol binding. These fi ndings are consistent with the hypothesis that drugs which can affect the C a2+-calmodulin/nitric oxide synthase/guanylyl cyclase signaling pathway may represent a novel approach to the treatment of depression and are congruen t with our previous observation, which has demonstrated the antidepressant- like properties of NO synthase inhibitors in the forced swim test. (C) 1999 Elsevier Science B.V. All rights reserved.